Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
EMBO Rep. 2004 Aug;5(8):825-30. Epub 2004 Jul 23.

HMGB1 is an endogenous immune adjuvant released by necrotic cells.

Author information

  • 1Cancer Immunotherapy & Gene Therapy Program, Clinical Immunology Unit H San Raffaele Scientific Institute and Vita-Salute San Raffaele University, DIBIT 3A1, Chromatin Dynamics Unit, Via Olgettina 58, 20132 Milano, Italy.

Abstract

Immune responses against pathogens require that microbial components promote the activation of antigen-presenting cells (APCs). Autoimmune diseases and graft rejections occur in the absence of pathogens; in these conditions, endogenous molecules, the so-called 'innate adjuvants', activate APCs. Necrotic cells contain and release innate adjuvants; necrotic cells also release high-mobility group B1 protein (HMGB1), an abundant and conserved constituent of vertebrate nuclei. Here, we show that necrotic HMGB1(-/-) cells have a reduced ability to activate APCs, and HMGB1 blockade reduces the activation induced by necrotic wild-type cell supernatants. In vivo, HMGB1 enhances the primary antibody responses to soluble antigens and transforms poorly immunogenic apoptotic lymphoma cells into efficient vaccines.

PMID:
15272298
[PubMed - indexed for MEDLINE]
PMCID:
PMC1299116
Free PMC Article

Images from this publication.See all images (4)Free text

Figure 1
Figure 2
Figure 3
Figure 4
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk